{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-109732","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.251418+00:00","generated_at":"2026-05-16T21:20:19.531209+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioXcel Q3 net loss $30.9M; plans sNDA for IGALMI at-home use in Q1 2026","bullets":["Net revenue of $98K from IGALMI, down from $214K YoY; cost of goods sold fell to $11K.","Net loss widened to $30.9M ($14.2M operating loss) from $13.7M loss a year ago; operating cash use $18.8M.","R&D expense rose to $8.7M (up $3.6M) due to SERENITY At-Home trial; SG&A fell to $5.4M.","Cash and equivalents $37.3M at Sep 30; raised $4.9M post-quarter via ATM.","Plans sNDA submission in early Q1 2026 for IGALMI at-home agitation treatment; revised addressable market to 57-77M annual episodes."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-109732","json":"https://secwatch.observer/filing/0001104659-25-109732.json","markdown":"https://secwatch.observer/filing/0001104659-25-109732.md","text":"https://secwatch.observer/filing/0001104659-25-109732.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925109732/0001104659-25-109732-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925109732/tm2530979d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:20:19.531209+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}